270 untreated patients, age between 18 and 65 years , with diffuse large B-cell lymphoma
(B-DLCL) were treated with a pegylated liposomal doxorubicin (PL-doxorubicin) modiﬁed
CHOP-rituximab regimen. PL-doxorubicin 35-40 mg/m(2)and epirubicin 70mg/m(2) were given in
combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab
(according to CHOP-R regimen) every 21 days for six courses.